The "Warburg effect" describes a peculiar metabolic feature of many solid tumors, namely their high glycolytic activity for biosynthesis and an inefficient generation of ATP. During aerobic glycolysis, pyruvate is preferentially metabolized to lactate by the enzyme lactate dehydrogenase-A (LDH-A), suggesting a possible vulnerability at this target for small molecule inhibition in cancer cells. In this study, we used FX11, a small molecule inhibitor of LDH-A, to investigate this possible vulnerability in a panel of 15 patient-derived mouse xenograft (PDX) models of pancreatic cancer. Unexpectedly, the p53 status of the PDX tumor determined the response to FX11. Tumors harboring wild-type (WT) TP53 were completely resistant to FX11. In contrast, tumors harboring mutant TP53 exhibited increased apoptosis, reduced proliferation indices and attenuated tumor growth when exposed to FX11. [ 
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer-related mortality in the United States, with an alarming rise in incidence and a projection that it will become the second most common cause of cancer deaths by 2030 (1). The 5-year survival rate of patients with advanced PDAC is <5%, which remained largely unchanged over the last four decades. The current treatment options for advanced PDAC include the multi-drug regimen FOLFIRINOX, or the combination of nab-paclitaxel plus gemcitabine (2) . However, neither therapy is curative, providing a median survival of 11 and 8.5 months, respectively. The dismal prognosis of PDAC patients underscores the urgent need to identify novel therapeutic targets that exploit the underlying mechanistic vulnerabilities in cancer cells.
Reprogramming of cellular metabolism is one of the hallmarks of cancer (3) . A critical aberration in metabolism that occurs in cancer cells is reflected in altered glucose metabolism.
In normal tissues, lactate generation through glycolysis, and the resulting inefficient ATP production, is limited to anaerobic conditions, while pyruvate typically feeds into mitochondrial oxidative phosphorylation (OXPHOS) when adequate oxygen levels are present. In contrast, cancer cells preferentially convert glucose into lactate through glycolysis, even under normal oxygen concentrations, a phenomenon termed "aerobic glycolysis" or the Warburg effect (4, 5) .
The enzyme lactate dehydrogenase-A (LDH-A) is involved in the conversion of pyruvate into lactate, utilizing NADH as a cofactor. By converting pyruvate to lactate, LDH-A regenerates the immune recognition (7) (8) (9) . The increase in glycolytic flux is a metabolic strategy of tumor cells to ensure survival and growth in nutrient-deprived environments (10).
LDH-A is up-regulated by various oncogenic transcription factors, such as HIF-1α and c-Myc, in cancers (11). Conversely, it has been documented that reduction of fermentative glycolysis through LDH-A blockade results in the inhibition of tumor growth and metastases in various preclinical models, implicating LDH-A as a viable therapeutic target (12) (13) (14) (15) (16) (17) . Blockade of LDH-A activity with the pharmacological inhibitor FX11 attenuates tumor progression across various preclinical models, including in PDAC cell lines (18) . Given the expanding portfolio of pharmacological inhibitors that target aberrant cancer metabolism (19, 20) , it is imperative that molecular determinants of sensitivity and resistance to these inhibitors be identified, and further, clinically feasible assays that can provide insights into in vivo response in real-time be developed. In this study, we demonstrate that PDAC tumors are responsive to FX11 treatment in a TP53-dependent manner. We further demonstrate that 13 C magnetic resonance spectroscopy (MRS) using hyperpolarized pyruvate provides a biochemically specific and clinically feasible approach for predicting in vivo response to LDH-A inhibition. 
MATERIALS AND METHODS

Patient-derived PDAC xenografts (PDXs)
All animal experiments were performed in accordance with the guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of Johns Hopkins University and the University of South Florida. Male nu/nu athymic mice (Harlan) were used for the study. Animals were maintained under pathogen-free conditions and a 12-hour light/12-hour dark cycle. Fresh PDAC specimens resected from patients at the time of surgery were implanted subcutaneously (s.c.) into the flanks of 6-weekold mice, as previously described (21, 22) . Grafted tumors were subsequently transplanted from mouse to mouse and maintained as a live PDX Bank in Johns Hopkins University, Baltimore as per the guidelines of Institutional Review Board-approved protocol.
In vivo efficacy of the LDH-A antagonist FX11 in patient-derived PDAC xenografts
Fifteen individual patient-derived PDAC xenografts were used for the FX11 study. The mutational status of common driver genes in PDAC has been previously described for these PDXs (23) . Briefly, subcutaneously established tumors were harvested at the exponential growth phase, and were cut aseptically into cubes of 1-2 mm 3 . The tumor pieces were dipped in matrigel and implanted on both flanks of 6-week-old male nu/nu athymic mice (Harlan). When cohorts of tumors reached ~200 mm 3 
Effect of FX11 treatment on Tumor cell proliferation and apoptosis
Excised tumors from the vehicle and FX11 treatment (harvested from the 28 day efficacy study) were fixed in 10% neutral buffered formalin and processed into paraffin blocks. Sections were deparaffinized in xylene and rehydrated in graded-alcohol washes. H&E staining was performed using standard procedure. The assessment of cellular proliferation was conducted using an anti-MIB-1 (Ki-67) antibody (clone K2, dilution 1:100, Ventana Medical Systems).
Immunohistochemical detection of apoptosis was performed using Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay with a commercial apoptosis detection kit (DeadEnd Fluorometric TUNEL System; Promega), according to the recommendations of the manufacturer. Stained sections were examined under light microscope and images were captured. Histograms for TUNEL and Ki-67 staining were generated by evaluating five high power fields of tumor section from two independent tumors per treatment arms (24) .
TP53-induced glycolysis regulator (TIGAR) and p53 Immunohistochemistry
Anti-TIGAR and anti-p53 antibodies (rabbit polyclonal to TIGAR, abcam, ab37910 and rabbit polyclonal to p53, abcam, ab4060) were used for TIGAR and p53 IHC, respectively. The staining was performed as per manufacture's protocol. Briefly, formalin fixed, paraffin embedded sections were deparaffinized and subjected to heat mediated antigen retrieval in citrate buffer prior to blocking in 10% serum for 1 hour at room temperature. The primary antibodies were diluted at 1/400 (TIGAR) and 1/100 (p53) and incubated with the sample for 1 hour at room temperature for TIGAR and 12 hours at 4°C for p53. A biotinylated goat anti-rabbit antibody was used as the secondary antibody (25, 26) . Stained sections were examined microscopically at 40x magnification and images were captured. The neoplastic areas were examined for staining and were graded according to the prevalence of both nuclear and cytoplasmic staining within 
Expression of human TIGAR transcripts in PDAC xenografts
Baseline TIGAR expression was determined in frozen tumors of two xenografts each with TP53 wild type and TP53 mutant status. Total RNA was extracted using RNeasy Mini Kit (Qiagen), Relative expression of the mRNA was estimated using the 2 −ΔΔCT method. Representative PDXs that were sensitive (JH015, P253) and resistant (JH024, JH033) to FX11 treatment were chosen for the hyperpolarized 13 C-MRS study and T 2 -weighted MRI measurements. Mice with 500 mm 3 subcutaneous tumors were selected for the imaging study.
Pyruvate sample preparation and animal handling
The jugular vein catheter was surgically implanted to facilitate polarized substrate injections.
The mice were treated with vehicle or FX11 (2.2 mg/kg) i.p. for seven consecutive days (N=4 mice/group).
In vivo 13 
C MR spectroscopy
As preparation for the MRI experiment, mice were infused with isofluorane in a plastic anesthesia chamber with scavenging. Anesthetized mice were placed in a mouse-specific holder within the MRI coil, outfitted with a mouse-specific nose cone inhalant anesthesia and scavenging system for imaging. This system also contains a pad for respiration monitoring, and endo-rectal fiber optic temperature monitoring device, a heated pad for maintaining core body 
RESULTS
Pharmacological LDH-A inhibition leads to tumor growth inhibition selectively in TP53 mutant PDAC xenografts
We sought to determine the treatment effect of FX11, a small molecule that can inhibit lactate dehydrogenase A (LDH-A), in a panel of 15 pancreatic cancer PDXs. A wide range of responses to 4 weeks of FX11 therapy was observed in these PDXs, with tumor growth inhibition (TGI) ranging from ~40% to a few PDXs reaching a marginally larger volume than the control group (Fig. 1A) . Overall, three of the PDXs had significant TGI with FX11 monotherapy (P253, JH015, and P194) (Fig. 1B) . In this panel, only two PDX were KRAS wild type (P410 and P420), and no specific pattern of response to FX11 was noted based on KRAS mutational status. Similarly SMAD4 mutational status did not yield any discernible pattern of response (Supplementary Table S1 ). On contrary, when the waterfall plot was segregated based on TP53 status, nearly all PDXs with any evident TGI (including the three tumors with significant inhibition) were TP53 mutant, while PDXs with minimal response or marginal enhancement in growth were uniformly TP53 wild type. We assessed proliferation (by Ki-67 nuclear labeling) and apoptosis (using TUNEL staining) in two TP53 wild type (JH033 and JH024) and two TP53 mutant (P253 and JH015) PDXs, and identified a significant reduction in proliferation, and a significant increase in apoptosis post-FX11 therapy that was restricted to the TP53 mutant xenografts ( Fig. 2 A and B) . Overall, these findings suggested that TP53 status is likely to be a key molecular determinant of response to pharmacological LDH-A inhibition.
We also measured the expression of the p53 target TIGAR, whose expression has been linked to decreased glycolytic conversion to pyruvate and lactate. Using immunohistochemistry, we found that TIGAR expression was positively correlated with TP53 wild type status, and its expression appeared diminished in TP53 mutant tumors (Fig. 3A and B) . Quantification of the p53 and TIGAR staining intensity in tumor sections of TP53 wild type PDXs revealed a significant increase in p53 and TIGAR expression compared to TP53 mutant PDXs (Fig. 3C) .
Baseline TIGAR mRNA expression was also reduced in TP53 mutant tumors compared to tumors with TP53 wild-type tumors, with a significant downregulation in one of two PDXs (Supplementary Fig. S1 ).
FDG-PET imaging of PDAC xenografts
In light of the differential responses to LDH-A inhibition, we interrogated the pattern of 18 Fdeoxy-glucose (FDG) uptake at baseline and following FX11 therapy in two PDXs, one with wild type TP53 (JH024) and the second with a TP53 mutant (JH015). The FDG uptake rates were different between JH024 and JH015 tumors. At baseline (D1), JH015 tumors had elevated FDG uptake compared to JH024, indicating greater reliance on glycolysis for energy production ( Fig.   4A and 4B) . Notably, there were no alterations in tumor FDG uptake following 7 days of FX11 therapy in JH024 (Fig. 4A) . In contrast, the avid glucose uptake observed in JH015 xenografts at baseline was significantly reduced following 7 days of FX11 therapy (Fig. 4B) . The recent development of hyperpolarized MR spectroscopic imaging methods to probe the biochemical and metabolic profile of tumors using 13 C-labeled pyruvate as the tracer, and then monitor its intracellular conversion to various metabolites, offers a unique opportunity to examine in vivo responses to metabolism-targeted therapies. In order to assess the metabolic conversion of hyperpolarized pyruvate to lactate, two sets of PDXs that were either sensitive to FX11 treatment (JH015 and P253, both TP53 mutant) or resistant to FX11 treatment (JH024 and JH033, both TP53 wild type), respectively, were chosen for hyperpolarized 13 C-MRS study. Representative dynamic 13 C MRS spectra of JH033 tumor (FX11 resistant) captured prior to FX11 treatment and 7 days FX11 treatment are shown in Fig. 5A and 5B, respectively.
Pyruvate and lactate peak intensities over time are shown in Fig. 5E and 5F. FX11 treatment was ineffective in altering the conversion flux from pyruvate to lactate in JH033. In contrast to the JH033 spectra, dynamic 13 C MRS spectra of P253 showed that pyruvate-to-lactate conversion was significantly reduced after seven days of FX11 treatment as compared to spectra captured prior to FX11 treatment ( Fig. 5C and 5D) , and this was confirmed in the pyruvate and lactate peak intensities over time ( Fig. 5G and 5H) . Seven days vehicle treatment did not alter the flux of hyperpolarized pyruvate to lactate conversion in both JH033 and P253 tumors ( 13 C MRS spectra not shown).
The integrated lactate-to-pyruvate ratio (Lac/Pyr) can be used to represent a drug therapy response marker in this study. The Lac/Pyr flux ratio was calculated from the area under the curve (as regarded a "Model-Free" approach) of the metabolic flux from the dynamic scan (30).
The Lac/Pyr flux ratios in response to FX11 treatments were significantly different between tumors sensitive (P253 and JH015) and resistant (JH024 and JH033) to FX11 treatment (Fig.   6A) . The Lac/Pyr ratios increased with time in the resistant (JH024 and JH033) tumors (Fig.   6A) . In stark contrast, the Lac/Pyr of both sensitive tumors (P253 and JH015) showed a striking decrease in response to FX11 treatment (Fig. 6A) . The tumor growth curves of representative tumors resistant (JH033) and sensitive (P253) to FX11 treatment are shown in Fig. 6B and 6C .
We also evaluated the unidirectional conversion rate constants (k p = pyruvate-to-lactate) using modified Bloch's equation of kinetic model (31). Consistent with the above results, the conversion rate constant (k p ) decreased in FX11 sensitive tumors and increased in FX11 resistant tumors ( Table 1) . PDXs had minimal FDG uptake. Of note, expression of TIGAR was higher in PDXs with wild type TP53 function, while TP53 mutations resulted in reduced TIGAR levels. TIGAR is a p53-inducible protein that functions to lower glycolytic flux and reduces cancer cell sensitivity to reactive oxygen species associated apoptosis (37-39). In TP53 wild type cells, TIGAR expression functions to decrease the levels of fructose-2-6-biphosphate, which suppresses glycolysis by diverting glucose-6-phosphate into the pentose phosphate pathway. The correlation of TIGAR expression with p53 status in pancreatic cancer PDXs could explain one potential mechanism for the reduced sensitivity to LDH-A inhibition in p53 wild type, high TIGAR cases, by reducing glycolytic dependence.
DISCUSSION
The understanding of cancer metabolism has deep roots in molecular biology and genetics but the ability to detect metabolism as it occurs in tumors without a biopsy is largely limited to PET imaging of enhanced glucose uptake into tumors using CAN-15-0108 
45.
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